Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
ISSN 0735-1097/$36.00
http://dx.doi.org/10.1016/j.jacc.2015.06.1323
ABSTRACT
BACKGROUND The incidence, predictors, and prognostic impact of post-discharge bleeding (PDB) after percutaneous
coronary intervention (PCI) with drug-eluting stent (DES) implantation are unclear.
OBJECTIVES This study sought to characterize the determinants and consequences of PDB after PCI.
METHODS The prospective ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) study was
used to determine the incidence and predictors of clinically relevant bleeding events occurring within 2 years after
hospital discharge. The effect of PDB on subsequent 2-year all-cause mortality was estimated by time-adjusted Cox
proportional hazards regression.
RESULTS Among 8,582 all-comers who underwent successful PCI with DES in the ADAPT-DES study, PDB occurred
in 535 of 8,577 hospital survivors (6.2%) at a median time of 300 days (interquartile range: 130 to 509 days)
post-discharge. Gastrointestinal bleeding (61.7%) was the most frequent source of PDB. Predictors of PDB included
older age, lower baseline hemoglobin, lower platelet reactivity on clopidogrel, and use of chronic oral anticoagulation
therapy. PDB was associated with higher crude rates of all-cause mortality (13.0% vs. 3.2%; p < 0.0001). Following
multivariable adjustment, PDB was strongly associated with 2-year mortality (hazard ratio [HR]: 5.03; p < 0.0001), with
an effect size greater than that of post-discharge myocardial infarction (PDMI) (HR: 1.92; p 0.009).
CONCLUSIONS After successful PCI with DES in an unrestricted patient population, PDB is not uncommon and has
a strong relationship with subsequent all-cause mortality, greater that that associated with PDMI. Efforts to reduce
PDB may further improve prognosis after successful DES implantation. (Assessment of Dual Antiplatelet Therapy With
Drug-Eluting Stents [ADAPT-DES]; NCT00638794) (J Am Coll Cardiol 2015;66:103645) 2015 by the American
College of Cardiology Foundation.
From the *Cardiovascular Research Foundation, New York, New York; yColumbia University Medical Center/NewYorkPresbyterian Hospital, New York, New York; zHpital du Sacr-Coeur de Montral, Montral, Qubec, Canada; xIcahn School of
Medicine at Mount Sinai, New York, New York; kHelios Amper-Klinikum, Dachau, Germany; {Shaare Zedek Medical Center, Jerusalem, Israel; #LeBauer Cardiovascular Research Foundation/Cone Health, Greensboro, North Carolina; **Sanger Heart &
Vascular Institute/Carolinas HealthCare System, Charlotte, North Carolina; yyUniversitts-Herzzentrum Freiburg Bad Krozingen,
Bad Krozingen, Germany; zzWellmont CVA Heart Institute, Kingsport, Tennessee; xxMinneapolis Heart Institute Foundation at
Abbott Northwestern Hospital, Minneapolis, Minnesota; kkCedars-Sinai Medical Center, Los Angeles, California; {{Lehigh Valley
Health Network, Allentown, Pennsylvania; ##Reid Heart Center, FirstHealth of the Carolinas, Pinehurst, North Carolina; ***The
Ohio State University Wexner Medical Center, Columbus, Ohio; and the yyyDipartimento Cardiovascolare, Policlinico S. Orsola,
University of Bologna, Bologna, Italy. Dr. Gnreux has received speakers honoraria from Abbott Vascular. Dr. Witzenbichler has
served as a consultant and member of the advisory board for Volcano. Dr. Stuckey has served on the advisory board for and
received speakers honoraria from Boston Scientic. Dr. Rinaldi has served as a consultant for Abbott, Boston Scientic, and St.
Jude Medical. Dr. Metzger has served as a consultant for Abbott Vascular, Cordis, IDEV, Medtronic, and Volcano; and has received
honoraria from Abbott Vascular, TriVascular, and Bard. Dr. Henry has served as a member of the scientic advisory board
for Abbott Vascular, Boston Scientic, and The Medicines Company; and of the steering committee for TRANSLATE,
Eli Lilly, and Daiichi-Sankyo. Dr. Cox has served as a consultant for Abbott Vascular, Boston Scientic, Medtronic, and The
Gnreux et al.
1037
ABBREVIATIONS
AND ACRONYMS
intervention
myocardial infarction
ST = stent thrombosis
In
contrast,
the
impact
and
MI = myocardial infarction
PCI = percutaneous coronary
PDMI = post-discharge
contribution
study.
years.
METHODS
specically
index procedure.
prospective,
multicenter
registry
with
aspirin
and
clopidogrel
were
eligible
for
Medicines Company. Dr. Duffy has received speaker honoraria from Volcano; and has served on the medical education advisory
board for Philips. Dr. Palmerini has received speakers honoraria from Abbott Vascular. Dr. Kirtane has received institutional
research grants to Columbia University from Boston Scientic, Medtronic, Abbott Vascular, Abiomed, St. Jude Medical, Vascular
Dynamics, and Eli Lilly. Dr. Mehran has received research grant support from Eli Lilly, AstraZeneca, The Medicines Company, and
BMS/Sano; served as a consultant for AstraZeneca, Bayer, CSL Behring, Janssen Pharmaceuticals, Merck & Co., Osprey Medical
Inc., and Watermark Research Partners (modest <$5,000/yr); served on the scientic advisory board for Abbott Laboratories,
Boston Scientic, Covidien, Janssen Pharmaceuticals, The Medicines Company, and Sano; given industry-sponsored lectures for
Mount Sinai School of Medicine (faculty occasionally give lectures at events sponsored by industry, but only if the events are free
of any marketing purposes) to PlatformQ; and has participated in other activities (including, but not limited to, committee
participation and data safety monitoring board membership) for Forest Laboratories (no payment). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Gnreux and Giustino contributed
equally to this work.
Listen to this manuscripts audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.
Manuscript received April 28, 2015; accepted June 19, 2015.
Gnreux et al.
Intervention
10
evaluated
in
the
present
study
1038
All bleedings
Bleedings without transfusion
Bleedings with transfusion
6.6%
4.7%
4
2
2.1%
0
0
9
12
15
18
Months After Discharge
21
24
over time in all patients; a similar pattern was seen when patients
revascularization.
respectively.
modeling
assumptions
were
checked
and
RESULTS
The
most
common
site
of
PDB
was
Gnreux et al.
61.7%
commonly
treated
with
oral
anti-
60
Bleeding Events (%)
were
1039
40
20
12.2%
8.6%
7.4%
7.0%
38/444
33/444
31/444
3.2%
274/444
54/444
CNS
14/444
Access Retroperitoneal
Site
Among 444 patients with bleeding and specied source, gastrointestinal bleeding was the
most predominant cause of post-discharge bleeding. CNS central nervous system.
groups.
The multivariable adjusted independent predictors
of PDB within 2-year follow-up were older age, pe-
(Table 2).
DISCUSSION
bleeding-related
complications
(3,5,6).
Nonetheless, some patients at high risk for thrombotic events, such as those with prior MI, might still
Gnreux et al.
1040
PDB (n 535)
No PDB
(n 8,042)
p Value
67.0 10.4
63.4 10.8
<0.0001
373 (69.7)
5,982 (74.4)
0.02
White
489 (91.4)
7,111 (88.4)
0.04
Bifurcation lesion
1.32 (1.061.64)
0.01
29.0 6.3
29.5 5.7
0.09
1.01 (1.011.02)
0.002
Baseline hemoglobin
(per g/dl decrease)
1.28 (1.221.37)
<0.0001
Variable*
Clinical characteristics
Age, yrs
Male
Diabetes mellitus
193 (36.1)
2,588 (32.2)
0.06
Hypertension
461 (86.2)
6,368 (79.2)
0.0001
Hyperlipidemia
427 (79.8)
5,949 (74.0)
0.003
Current smoker
111 (20.7)
1,829 (22.7)
0.29
Previous MI
158 (29.5)
2,006 (24.9)
0.02
Previous PCI
0.0007
HR (95% CI)
p Value
1.02 (1.011.03)
<0.0001
<0.0001
Warfarin, at discharge
2.31 (1.782.99)
1.57 (1.251.98)
0.0001
Calcied lesion
1.25 (1.051.50)
0.01
*The candidate covariates considered for inclusion in the model were: in-hospital
bleeding, age, male sex, diabetes, hypertension, hyperlipidemia, congestive heart
failure, peripheral arterial disease, creatinine clearance, pervious percutaneous
coronary intervention, ST-segment elevation MI, baseline hemoglobin, warfarin at
discharge, triple vessel disease, left main disease, coronary calcication, bifurcation, chronic total occlusion, number of vessels treated, number of lesion treated,
stents implanted, mechanical closure device used, P2Y12 reactivity units, and
aspirin reactivity units.
267 (49.9)
3,411 (42.4)
Previous CABG
113 (21.1)
1,354 (16.8)
0.01
92 (17.2)
782 (9.7)
<0.0001
Renal insufciency
87 (16.3)
571 (7.1)
<0.0001
24 (4.5)
114 (1.4)
<0.0001
69 (12.9)
630 (7.8)
<0.0001
Ejection fraction, %
55.0 13.71
54.9 12.34
0.91
199 (37.2)
2,376 (29.5)
0.0002
278 (52.0)
3,871 (48.1)
0.09
257 (48.0)
4,171 (51.9)
0.08
Unstable angina
147 (27.5)
2,219 (27.6)
0.95
NonST-segment elevation MI
80 (15.0)
1,168 (14.5)
0.79
ST-segment elevation MI
30 (5.6)
784 (9.7)
0.002
13.3 1.6
14.0 1.5
<0.0001
228.7 70.4
226.6 62.5
8.30 4.85
7.93 3.05
0.08
83.0 40.0
94.8 37.1
<0.0001
Dialysis
Clinical presentation
Hemoglobin, g/dl
3
0.51
of
oral
anticoagulation.
352 (4.4)
0.93
14 (0.2)
0.02
170 (31.8)
3,112 (38.7)
0.001
174 (32.5)
2,659 (33.1)
0.80
Radial
23 (4.3)
Brachial
4 (0.7)
1
2
use
7,676 (95.4)
concomitant
0.60
508 (95.0)
and
0.0002
0.1
0.01
carrying capacity
1.7 1.0
0.009
191 (35.7)
2,271 (28.2)
1.6 0.8
1.5 0.8
29.2 21.0
26.9 20.0
1.8 1.1
resulting
in
hypotension
and
35.0 23.4
32.3 22.3
0.006
40 (7.5)
748 (9.3)
0.15
Post-procedural TIMI ow 3
530 (99.1)
7,995 (99.4)
0.40
Thrombus
69 (12.9)
1,213 (15.1)
0.17
Calcied lesion
211 (39.4)
2,433 (30.2)
<0.0001
Bifurcation lesion
104 (19.4)
1,222 (15.2)
0.008
33 (6.2)
372 (4.6)
0.10
242/658 (36.8)
3,707/9,450 (39.2)
0.21
202/658 (30.7)
2,984/9,450 (31.6)
0.63
36/658 (5.5)
208 (38.9)
3153 (39.2)
Location
0.0004
0.89
Values are n (%) or mean SD. *Calculated by Cockcroft-Gault formula. Lesion-level analysis, reported as
n/total lesion N (%).
CABG coronary artery bypass graft; MI myocardial infarction; PCI percutaneous coronary intervention;
TIMI Thrombolysis In Myocardial Infarction.
Gnreux et al.
PDB
(n 535)
No PDB
(n 8,042)
Unadjusted
HR (95% CI)
p Value*
13.0 (68)
3.2 (243)
8.14 (5.5312.00)
<0.0001
Cardiac
5.1 (25)
1.9 (144)
4.95 (2.649.28)
<0.0001
Noncardiac
6.1 (31)
1.2 (87)
10.52 (5.8918.81)
<0.0001
All-cause mortality
MI
cause
mortality
than
1041
PDB
without
transfusion.
MACE
13.5 (68)
4.1 (319)
3.14 (2.024.90)
<0.0001
20.6 (103)
9.0 (685)
2.59 (1.833.68)
<0.0001
1.5 (8)
1.0 (81)
3.63 (1.2910.24)
24.1 (123)
9.9 (758)
2.89 (2.103.97)
0.02
<0.0001
Event rates are Kaplan-Meier estimates reported as % (n). *Wald p value. Composite of cardiac death, MI, or
target lesion revascularization.
MACE major adverse cardiac event(s); other abbreviations as in Table 1.
(perhaps in concert with essential medication discontinuation) rather than transfusions that may
Early discontinuation of or removing aspirin
affect prognosis.
Not surprisingly, concomitant use of oral antico-
diphosphateassociated
platelet
activation)
were
requiring warfarin
consistent
with
the
ADAPT-DES
study,
which
Post-discharge bleeding
clinical utility in using PRU to guide treatment decisions. Given the higher rate and prognostic impact
of PDB compared to PDMI, coupled with the im-
9
6
study
suggests
that
future
0
0
in-
vestigations might explore the role of PRU monitoring in high bleeding risk patients to ensure that
P2Y12 receptor-mediated platelet inhibition is not
greater than necessary.
12
15
18
9
Months After Discharge
21
24
8
6.8%
6
6.4%
4
p = 0.45
2
0
30
p <0.0001
1.4%
0.4%
0.2%
0 30
PDB 535 529 520 506 492 480 467 461 289
No PDB 8,042 7,840 7,795 7,756 7,631 7,446 7,369 7,306 4,739
Number at risk
our
5.1%
3.2%
1.9%
13.0%
12
Mortality (%)
p <0.0001 p <0.0001
No post-discharge bleeding
15
90
p <0.0001
1.7%
Number at risk
PDB
No PDB
535
532 529 520 506 489 480 467 461 265
8,042 7,935 7,840 7,795 7,756 7,619 7,446 7,369 7,306 4,407
improve patient prognosis. Moreover, the predominance of gastrointestinal bleeding highlights the need
for judicious screening (e.g., careful history, selective
Kaplan-Meier estimates demonstrate higher rates of all-cause mortality (solid line) and
cardiac mortality (dotted line) according to the occurrence of post-discharge bleeding
(PDB) (salmon) compared to no PDB (blue) over 2 years of follow-up (A) as well as the
1042
Gnreux et al.
2 Years
A
All-Cause Mortality (%)
18
Adjusted HR
(95% CI)
Variable*
16.2%
15
12
11.6%
9
6
3.2%
3
0
0
9
12
15
18
Months Since Discharge
21
24
Number at risk
PDB with transfusion 168
167
162 160
154
150 144 140
77
321
211
PDB without transfusion 367 362 358 346 338 330 323
No PDB 8,042 7,840 7,795 7,756 7,631 7,446 7,369 7,306 4,739
p Value
PDB
With transfusion
Without transfusion
Post-discharge MI
1.92 (1.183.12)
0.009
Current smoker
1.69 (1.252.29)
0.001
Male
1.45 (1.111.90)
0.007
Diabetes mellitus
1.48 (1.171.88)
0.001
Previous MI
1.42 (1.121.81)
0.004
1.41 (1.101.83)
0.008
1.22 (0.961.54)
0.10
IVUS use
0.83 (0.651.06)
0.13
Creatinine clearance
(per ml/min increase)
0.99 (0.991.00)
0.0007
1.03 (1.011.04)
<0.0001
8
7.0%
6
4.3%
1.9%
*The candidate covariates considered for inclusion in the model were: PDB,
post-discharge MI, age, male, diabetes, current smoker, previous MI, baseline
presentation with ST-segment elevation MI (STEMI) or non-STEMI (vs. stable
coronary artery disease), hyperlipidemia, baseline hemoglobin, baseline white
blood cells, baseline platelets, creatinine clearance, VerifyNow P2Y12 reactivity
units >208, and intravascular ultrasound (IVUS) guidance. Both variables were
included as time-dependent covariates. Calculated by the Cockcroft-Gault
formula.
Abbreviations as in Table 1.
0
0
9
12
15
18
Months Since Discharge
21
24
Number at risk
PDB with transfusion 168
167
162 160 154
150 144 140
77
PDB without transfusion 367 362 358 346 338 330 323
321
211
No PDB 8,042 7,840 7,795 7,756 7,631 7,446 7,369 7,306 4,739
Post-discharge bleeding
with transfusion
Post-discharge bleeding
without transfusion
No post-discharge
bleeding
reactivity
to
aspirin
and
clopidogrel.
those with no transfusions, but those rates cross between 9 and 12 months and climb more
sharply thereafter.
NCT01830543; NCT02164864).
Gnreux et al.
CENTRAL I LLU ST RAT ION Post-Discharge Bleeding After PCI: Predictors and Impact of
Clinically Signicant Bleeding on Mortality
BLEEDING
DAPT
discontinuation
Blood
extravasation
Blood
transfusion
Rebound platelet
reactivity
Hemoglobin drop
Hypovolemia/
hypotension
Transfusion-related
effects
Inflammatory
cascade activation
+
Incomplete stent
endothelialization
Vasoconstriction
Decreased
oxygen delivery
Platelet
aggregation
Cardiac or
cerebrovascular event
DEATH
Pathophysiological mechanisms linking out-of-hospital clinically signicant bleeding and mortality after implantation of drug-eluting stents
(DES). Several clinical and pharmacological factors increase the propensity for bleeding under dual antiplatelet therapy (DAPT). Hemorrhagic
events lead to mortality through a direct effect (central pathway) by reducing circulating blood volume as well as reducing blood oxygencarrying capacity and tissue hypoxia; and through indirect effect (lateral pathways) by increasing the risk for stent thrombosis (because of
sudden DAPT discontinuation with rebound in platelet reactivity while the DES is still partially endothelialized) as well as cardiac and
noncardiac ischemic events associated with increased thrombogenicity after blood transfusions. Preventing out-of-hospital bleeding after DES
implantation may signicantly improve survival and long-term prognosis after percutaneous coronary revascularization (PCI).
cannot be excluded.
CONCLUSIONS
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
gs2184@columbia.edu.
1043
1044
Gnreux et al.
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCE-
REFERENCES
1. Mehran R, Giustino G, Baber U. DAPT duration
after DES: what is the mandatory duration? J Am
Coll Cardiol 2015;65:11036.
2. Yeh RW, Mauri L, Kereiakes DJ. Dual antiplatelet
platelet therapy duration following coronary
stenting. J Am Coll Cardiol 2015;65:78790.
3. Palmerini T, Sangiorgi D, Valgimigli M, et al.
Short- versus long-term dual antiplatelet therapy
after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. J Am Coll Cardiol 2015;65:1092102.
4. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve
or 30 months of dual antiplatelet therapy after
drug-eluting stents. N Engl J Med 2014;371:
215566.
5. Giustino G, Baber U, Sartori S, et al. Duration of
dual antiplatelet therapy after drug-eluting stent
implantation: a systematic review and metaanalysis of randomized controlled trials. J Am
Coll Cardiol 2015;65:1298310.
6. Palmerini T, Benedetto U, Bacchi-Reggiani L,
et al. Mortality in patients treated with extended
duration dual antiplatelet therapy after drugeluting stent implantation: a pairwise and
Bayesian network meta-analysis of randomised
trials. Lancet 2015;385:237182.
7. Mehran R, Pocock S, Nikolsky E, et al. Impact of
bleeding on mortality after percutaneous coronary
intervention results from a patient-level pooled
analysis of the REPLACE-2 (randomized evaluation
of PCI linking angiomax to reduced clinical
events), ACUITY (acute catheterization and urgent
intervention triage strategy), and HORIZONS-AMI
(harmonizing outcomes with revascularization
and stents in acute myocardial infarction) trials.
J Am Coll Cardiol Intv 2011;4:65464.
8. Steg PG, Huber K, Andreotti F, et al. Bleeding in
acute coronary syndromes and percutaneous coronary interventions: position paper by the Working
Group on Thrombosis of the European Society of
Cardiology. Eur Heart J 2011;32:185464.
9. Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after
percutaneous coronary interventions: appropriateness of including bleeding as a component of a
with long-term mortality after percutaneous coronary intervention. J Am Coll Cardiol 2015;65:
141120.
11. Stone GW, Witzenbichler B, Weisz G, et al.
Platelet reactivity and clinical outcomes after
coronary artery implantation of drug-eluting
stents (ADAPT-DES): a prospective multicentre
registry study. Lancet 2013;382:61423.
12. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:220316.
13. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for
standardized denitions. Circulation 2007;115:
234451.
14. Bonaca MP, Bhatt DL, Cohen M, et al. Longterm use of ticagrelor in patients with prior
myocardial infarction. N Engl J Med 2015;72:
1791800.
15. Yadav M, Genereux P, Palmerini T, et al. SYNTAX score and the risk of stent thrombosis after
percutaneous coronary intervention in patients
with non-ST-segment elevation acute coronary
syndromes: an ACUITY trial substudy. Catheter
Cardiovasc Interv 2015;85:110.
16. Madhavan MV, Genereux P, Palmerini T, et al.
The association between the extent of coronary
artery disease and major bleeding events after
percutaneous coronary intervention: from the
ACUITY trial. J Invasive Cardiol 2015;27:20311.
17. Gnreux P, Madhavan MV, Mintz GS, et al.
Relation between coronary calcium and major
bleeding after percutaneous coronary intervention
in acute coronary syndromes (from the Acute
Catheterization and Urgent Intervention Triage
Strategy and Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial
Infarction Trials). Am J Cardiol 2014;113:9305.
18. Mehran R, Baber U, Steg PG, et al. Cessation of
dual antiplatelet treatment and cardiac events
after percutaneous coronary intervention (PARIS):
Gnreux et al.
27. Gnreux P, Cohen DJ, Mack M, et al. Incidence, predictors, and prognostic impact of late
bleeding complications after transcatheter aortic
valve replacement. J Am Coll Cardiol 2014;64:
32. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute
coronary syndromes. N Engl J Med 2009;361:
104557.
260515.
1045